- call +1-201-465-4211
- email sales@mrinsights.biz
Non-insulin diabetes therapeutics are mostly administered orally and prescribed when diet and exercise are insufficient to control elevated blood glucose levels.
Scope of the Report:
This report studies the Non-insulin Diabetes Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-insulin Diabetes Therapeutics market by product type and applications/end industries.
The global Non-insulin Diabetes Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Non-insulin Diabetes Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
GSK
Eli Lilly
Sumitomo Dainippon Pharma
Intarcia Therapeutics
Servier
Jiangsu Hansoh Pharmaceutical
Novo Nordisk
Emisphere
Uni-Bio Science Group
Takeda
3SBio
Merck
Dong-A Pharmaceutical
Luye Pharma Group
Eurofarma
Geropharm
Alkem Labs
SatRx
Pfizer
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
DPP4 inhibitor
GLP-1 agonist
SGLT2 inhibitor
Market Segment by Applications, can be divided into
Hospital Pharmacy
Retail Pharmacies
Online Pharmacy
Others
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Non-insulin Diabetes Therapeutics Market Overview
1.1 Product Overview and Scope of Non-insulin Diabetes Therapeutics
1.2 Classification of Non-insulin Diabetes Therapeutics by Types
1.2.1 Global Non-insulin Diabetes Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Non-insulin Diabetes Therapeutics Revenue Market Share by Types in 2017
1.2.3 DPP4 inhibitor
1.2.4 GLP-1 agonist
1.2.5 SGLT2 inhibitor
1.3 Global Non-insulin Diabetes Therapeutics Market by Application
1.3.1 Global Non-insulin Diabetes Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Non-insulin Diabetes Therapeutics Market by Regions
1.4.1 Global Non-insulin Diabetes Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Non-insulin Diabetes Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-insulin Diabetes Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-insulin Diabetes Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Non-insulin Diabetes Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-insulin Diabetes Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Non-insulin Diabetes Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 GSK
2.1.1 Business Overview
2.1.2 Non-insulin Diabetes Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GSK Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eli Lilly
2.2.1 Business Overview
2.2.2 Non-insulin Diabetes Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Eli Lilly Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Sumitomo Dainippon Pharma
2.3.1 Business Overview
2.3.2 Non-insulin Diabetes Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Sumitomo Dainippon Pharma Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Intarcia Therapeutics
2.4.1 Business Overview
2.4.2 Non-insulin Diabetes Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Intarcia Therapeutics Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Servier
2.5.1 Business Overview
2.5.2 Non-insulin Diabetes Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Servier Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Jiangsu Hansoh Pharmaceutical
2.6.1 Business Overview
2.6.2 Non-insulin Diabetes Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Jiangsu Hansoh Pharmaceutical Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Novo Nordisk
2.7.1 Business Overview
2.7.2 Non-insulin Diabetes Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Novo Nordisk Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Emisphere
2.8.1 Business Overview
2.8.2 Non-insulin Diabetes Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Emisphere Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Uni-Bio Science Group
2.9.1 Business Overview
2.9.2 Non-insulin Diabetes Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Uni-Bio Science Group Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 Takeda
2.10.1 Business Overview
2.10.2 Non-insulin Diabetes Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 Takeda Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 3SBio
2.11.1 Business Overview
2.11.2 Non-insulin Diabetes Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 3SBio Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.12 Merck
2.12.1 Business Overview
2.12.2 Non-insulin Diabetes Therapeutics Type and Applications
2.12.2.1 Product A
2.12.2.2 Product B
2.12.3 Merck Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.13 Dong-A Pharmaceutical
2.13.1 Business Overview
2.13.2 Non-insulin Diabetes Therapeutics Type and Applications
2.13.2.1 Product A
2.13.2.2 Product B
2.13.3 Dong-A Pharmaceutical Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.14 Luye Pharma Group
2.14.1 Business Overview
2.14.2 Non-insulin Diabetes Therapeutics Type and Applications
2.14.2.1 Product A
2.14.2.2 Product B
2.14.3 Luye Pharma Group Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.15 Eurofarma
2.15.1 Business Overview
2.15.2 Non-insulin Diabetes Therapeutics Type and Applications
2.15.2.1 Product A
2.15.2.2 Product B
2.15.3 Eurofarma Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.16 Geropharm
2.16.1 Business Overview
2.16.2 Non-insulin Diabetes Therapeutics Type and Applications
2.16.2.1 Product A
2.16.2.2 Product B
2.16.3 Geropharm Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.17 Alkem Labs
2.17.1 Business Overview
2.17.2 Non-insulin Diabetes Therapeutics Type and Applications
2.17.2.1 Product A
2.17.2.2 Product B
2.17.3 Alkem Labs Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.18 SatRx
2.18.1 Business Overview
2.18.2 Non-insulin Diabetes Therapeutics Type and Applications
2.18.2.1 Product A
2.18.2.2 Product B
2.18.3 SatRx Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.19 Pfizer
2.19.1 Business Overview
2.19.2 Non-insulin Diabetes Therapeutics Type and Applications
2.19.2.1 Product A
2.19.2.2 Product B
2.19.3 Pfizer Non-insulin Diabetes Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Non-insulin Diabetes Therapeutics Market Competition, by Players
3.1 Global Non-insulin Diabetes Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-insulin Diabetes Therapeutics Players Market Share
3.2.2 Top 10 Non-insulin Diabetes Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Non-insulin Diabetes Therapeutics Market Size by Regions
4.1 Global Non-insulin Diabetes Therapeutics Revenue and Market Share by Regions
4.2 North America Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Non-insulin Diabetes Therapeutics Revenue by Countries
5.1 North America Non-insulin Diabetes Therapeutics Revenue by Countries (2013-2018)
5.2 USA Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Non-insulin Diabetes Therapeutics Revenue by Countries
6.1 Europe Non-insulin Diabetes Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Non-insulin Diabetes Therapeutics Revenue by Countries
7.1 Asia-Pacific Non-insulin Diabetes Therapeutics Revenue by Countries (2013-2018)
7.2 China Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Non-insulin Diabetes Therapeutics Revenue by Countries
8.1 South America Non-insulin Diabetes Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Non-insulin Diabetes Therapeutics by Countries
9.1 Middle East and Africa Non-insulin Diabetes Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Non-insulin Diabetes Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Non-insulin Diabetes Therapeutics Market Segment by Type
10.1 Global Non-insulin Diabetes Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Non-insulin Diabetes Therapeutics Market Forecast by Type (2018-2023)
10.3 DPP4 inhibitor Revenue Growth Rate (2013-2023)
10.4 GLP-1 agonist Revenue Growth Rate (2013-2023)
10.5 SGLT2 inhibitor Revenue Growth Rate (2013-2023)
11 Global Non-insulin Diabetes Therapeutics Market Segment by Application
11.1 Global Non-insulin Diabetes Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Non-insulin Diabetes Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospital Pharmacy Revenue Growth (2013-2018)
11.4 Retail Pharmacies Revenue Growth (2013-2018)
11.5 Online Pharmacy Revenue Growth (2013-2018)
11.6 Others Revenue Growth (2013-2018)
12 Global Non-insulin Diabetes Therapeutics Market Size Forecast (2018-2023)
12.1 Global Non-insulin Diabetes Therapeutics Market Size Forecast (2018-2023)
12.2 Global Non-insulin Diabetes Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Non-insulin Diabetes Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Non-insulin Diabetes Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Non-insulin Diabetes Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Non-insulin Diabetes Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Non-insulin Diabetes Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Non-insulin Diabetes Therapeutics Picture
Table Product Specifications of Non-insulin Diabetes Therapeutics
Table Global Non-insulin Diabetes Therapeutics and Revenu
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
